Isotechnika Pharma Inc IPHAF

Lux buying ISA

[ngerrits]

It is becoming evident that CEO Mitchell (Lux) should buy ISA:

FDA approval triggers $7M payment to ISA.

EMA approval triggers $3.5 payment to ISA

total if both approved = $10.5M or
.08 per share.

Lux would avoid paying any royalty to ISA aswell and have a public listing.  A BIG THING.

I guess the question is will Palidan sell?  they seem to be content on using the tax benefits of ISA and not give a s__T on what else happens.  You would think they would like to see fda approval and therefore use there marketing expertise to help Lux get doctors prescriping vocsporin.

This thing just boggles my mind.   no negotiating leverage whatsoever.

[teevee]

If Lux's deal survives an ISA bankruptcy, Lux wouldn't have to buy ISA. Paladin can manufacture the drug for any additional trials. Who knows, maybe Lux could get out of paying any milestone payments too? If Lux's deal doesn't survive an ISA bankruptcy, then I would offer say $.8/share on a share exchange ratio, which might be on the order of 1 Lux share for each 1000 ISA shares